Rebalix
Logo AmundiAmundi · sheet of 10 September 2026
ETF sheet · official issuer and register data

Amundi JPX-NIKKEI 400 UCITS ETF EUR Acc

JPNK · LU1681038912 · class UCITS ETF EUR Acc · EUR · domicile Luxembourg
Equity · JapanSFDR art. 6
Index tracked: JPX Nikkei Net Total Return Index
TER
0.18%+ trans. 0.00%
Fund size
60 m EUR
Tracking difference
−0.22%3-year avg
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Synthetic (swap)
Income
Accumulating
Launch 21 Mar 2018 · costs from the KID as of 2 Sept 2026 · 37 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
This Sub-Fund is passively managed. The objective of this Sub-Fund is to track the performance of JPX-Nikkei 400 Index, and to minimize the tracking error between the net asset value of the Sub-Fund and the performance of the Index. The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund. The Index is a Net Total Return Index : dividends net of tax paid by the index constituents are included in the Index return. JPX-Nikkei 400 Index is an equity index representative of the Japanese…

Performance since series start (in euro) — base 100

22 Mar 20188 Sept 2026 · dividends reinvested where declared by the issuer
201920212023202520583201
High 205 (7 Sept 2026) · low 83 (16 Mar 2020) · last 201. Past performance is not indicative of future results.

Returns in euro

1 year+27.7%
3 years+59.1%
5 years+56.0%
10 yearsseries too young
Since series start+101.5%

Risk · 1 / 3 / 5 years

Volatility (ann.)19.75%21.11%19.54%
Max drawdown−11.16%−18.06%−21.05%
Sharpe1.190.670.41
Sortino1.770.950.58
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · JPNK · LU16810389121
RebalixJPNK · LU1681038912 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+9.81%+10.04%−0.23%
2024+14.84%+15.02%−0.19%
2023+15.70%+15.94%−0.24%
2022−10.01%−9.83%−0.19%
2021+7.88%+8.12%−0.24%

Holdings

Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 1 Sept 2026 · 37 securities · top-10 weight = 60.8%
Top holdingsWeight
APPLE INC9.1%
CVS HEALTH CORP8.9%
APPLIED MATERIALS INC8.6%
AMAZON.COM INC8.2%
ABBVIE INC4.5%
JOHNSON & JOHNSON4.4%
MICROSOFT CORP4.3%
MICRON TECHNOLOGY INC4.3%
META PLATFORMS INC-CLASS A4.3%
NVIDIA CORP4.2%

Listing venues

ESMA register (FIRDS) and official exchange lists
· Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange
JPNK · Euronext Paris
JP40 · Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.amundietf.it/pdfDocuments/kid-priips/LU1681038912/ENG/NLD
Factsheet · www.amundietf.it/pdfDocuments/monthly-factsheet/LU1681038912/ENG/GBR/I
Prospectus · www.amundietf.it/pdfDocuments/prospectus/LU1681038912/ENG/GBR
The live sheet, always up to date
rebalix.com/en/etf/LU1681038912
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · JPNK · LU16810389122